Anti-adhesion therapies in inflammatory bowel disease-molecular and clinical aspects

Frontiers in Immunology

Volumn 8, Issue JUL, 2017, Pages

  Zundler, Sebastian ^a   Becker, Emily ^a   Weidinger, Carl ^b,c   Siegmund, Britta ^b  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c BERLIN INSTITUTE OF HEALTH   (Germany)

Author keywords

Crohn's disease; Etrolizumab; Gut homing; Inflammatory bowel diseases; Integrins; Natalizumab; Ulcerative colitis; Vedolizumab

Indexed keywords

ALPHA4 INTEGRIN; BETA7 INTEGRIN; ETROLIZUMAB; NATALIZUMAB; VASCULAR CELL ADHESION MOLECULE 1; VEDOLIZUMAB;

ARTHRALGIA; CELL HOMING; CELL MIGRATION; CHRONIC INFLAMMATION; CLINICAL FEATURE; CROHN DISEASE; DRUG EFFICACY; DRUG SAFETY; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TRACT; HUMAN; INFLAMMATORY INFILTRATE; INTESTINE CELL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PROTEIN PROTEIN INTERACTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REMISSION; RHINOPHARYNGITIS; SHORT SURVEY; SIDE EFFECT; T LYMPHOCYTE; TREATMENT RESPONSE; ULCERATIVE COLITIS;

EID: 85026501006     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2017.00891     Document Type: Short Survey

References (62)

1. Lönnfors S, Vermeire S, Avedano L. IBD and health-related quality of life-discovering the true impact. J Crohns Colitis (2014) 8:1281-6. doi:10.1016/j.crohns.2014.03.005
2. Jostins L, Ripke S, Weersma RK, Duerr RH, McGovern DP, Hui KY, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature (2012) 491:119-24. doi:10.1038/nature11582
3. Siegmund B, Zeitz M. Clinical aspects of inflammatory bowel disease. Eur J Immunol (2009) 39:2026-30. doi:10.1002/eji.200939601
4. Neurath MF. Cytokines in inflammatory bowel disease. Nat Rev Immunol (2014) 14:329-42. doi:10.1038/nri3661
5. Shih DQ, Targan SR, McGovern D. Recent advances in IBD pathogenesis: genetics and immunobiology. Curr Gastroenterol Rep (2008) 10:568-75. doi:10.1007/s11894-008-0104-x
6. Monteleone G, Caprioli F. T-cell-directed therapies in inflammatory bowel diseases. Clin Sci (Lond) (2010) 118:707-15. doi:10.1042/CS20100027
7. Sturm A, de Souza HSP, Fiocchi C. Mucosal T cell proliferation and apoptosis in inflammatory bowel disease. Curr Drug Targets (2008) 9:381-7. doi:10.2174/138945008784221198
8. Ley K, Laudanna C, Cybulsky MI, Nourshargh S. Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat Rev Immunol (2007) 7:678-89. doi:10.1038/nri2156
9. Mora JR, Bono MR, Manjunath N, Weninger W, Cavanagh LL, Rosemblatt M, et al. Selective imprinting of gut-homing T cells by Peyer's patch dendritic cells. Nature (2003) 424:88-93. doi:10.1038/nature01726
10. Iwata M, Hirakiyama A, Eshima Y, Kagechika H, Kato C, Song S-Y. Retinoic acid imprints gut-homing specificity on T cells. Immunity (2004) 21:527-38. doi:10.1016/j.immuni.2004.08.011
11. Mora JR. Homing imprinting and immunomodulation in the gut: role of dendritic cells and retinoids. Inflamm Bowel Dis (2008) 14:275-89. doi:10.1002/ibd.20280
12. von Andrian UH, Mackay CR. T-cell function and migration-two sides of the same coin. N Engl J Med (2000) 343:1020-34. doi:10.1056/NEJM200010053431407
13. Briskin M, Winsor-Hines D, Shyjan A, Cochran N, Bloom S, Wilson J, et al. Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue. Am J Pathol (1997) 151:97-110.
14. Berlin C, Berg EL, Briskin MJ, Andrew DP, Kilshaw PJ, Holzmann B, et al. Alpha 4 beta 7 integrin mediates lymphocyte binding to the mucosal vascular addressin MAdCAM-1. Cell (1993) 74:185-95. doi:10.1016/0092-8674(93)90305-A
15. Montresor A, Toffali L, Constantin G, Laudanna C. Chemokines and the signaling modules regulating integrin affinity. Front Immunol (2012) 3:127. doi:10.3389/fimmu.2012.00127
16. Luo B-H, Carman CV, Springer TA. Structural basis of integrin regulation and signaling. Annu Rev Immunol (2007) 25:619-47. doi:10.1146/annurev.immunol.25.022106.141618
17. Zundler S, Fischer A, Schillinger D, Binder M-T, Atreya R, Rath T, et al. The α4β1 homing pathway is essential for ileal homing of Crohn's disease effector T cells in vivo. Inflamm Bowel Dis (2017) 23:379-91. doi:10.1097/MIB.0000000000001029
18. Ostermann G, Weber KSC, Zernecke A, Schröder A, Weber C. JAM-1 is a ligand of the β2 integrin LFA-1 involved in transendothelial migration of leukocytes. Nat Immunol (2002) 3:151-8. doi:10.1038/ni755
19. Bromley SK, Thomas SY, Luster AD. Chemokine receptor CCR7 guides T cell exit from peripheral tissues and entry into afferent lymphatics. Nat Immunol (2005) 6:895-901. doi:10.1038/ni1240
20. Mandala S, Hajdu R, Bergstrom J, Quackenbush E, Xie J, Milligan J, et al. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science (2002) 296:346-9. doi:10.1126/science.1070238
21. Zundler S, Neurath MF. Novel insights into the mechanisms of gut homing and antiadhesion therapies in inflammatory bowel diseases. Inflamm Bowel Dis (2017) 23:617-27. doi:10.1097/MIB.0000000000001067
22. Cepek KL, Parker CM, Madara JL, Brenner MB. Integrin alpha E beta 7 mediates adhesion of T lymphocytes to epithelial cells. J Immunol (1993) 150:3459-70.
23. Gorfu G, Rivera-Nieves J, Ley K. Role of β7 integrins in intestinal lymphocyte homing and retention. Curr Mol Med (2009) 9:836-50. doi:10.2174/156652409789105525
24. Lobatón T, Vermeire S, Van Assche G, Rutgeerts P. Review article: anti-adhesion therapies for inflammatory bowel disease. Aliment Pharmacol Ther (2014) 39:579-94. doi:10.1111/apt.12639
25. Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel J-F, Sandborn WJ, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med (2013) 369:699-710. doi:10.1056/NEJMoa1215734
26. Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel J-F, Sands BE, et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med (2013) 369:711-21. doi:10.1056/NEJMoa1215739
27. Sandborn WJ, Colombel JF, Enns R, Feagan BG, Hanauer SB, Lawrance IC, et al. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med (2005) 353:1912-25. doi:10.1056/NEJMoa043335
28. Podolsky DK, Lobb R, King N, Benjamin CD, Pepinsky B, Sehgal P, et al. Attenuation of colitis in the cotton-top tamarin by anti-alpha 4 integrin monoclonal antibody. J Clin Invest (1993) 92:372-80. doi:10.1172/JCI116575
29. Hesterberg P, Winsor-Hines D, Briskin M, Soler-Ferran D, Merrill C, Mackay C, et al. Rapid resolution of chronic colitis in the cotton-top tamarin with an antibody to a gut-homing integrin alpha 4 beta 7. Gastroenterology (1996) 111:1373-80. doi:10.1053/gast.1996.v111.pm8898653
30. Van Assche G, Van Ranst M, Sciot R, Dubois B, Vermeire S, Noman M, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med (2005) 353:362-8. doi:10.1056/NEJMoa051586
31. Siegmund B. Targeted therapies in inflammatory bowel disease. Dig Dis (2009) 27:465-9. doi:10.1159/000233284
32. Amiot A, Grimaud J-C, Peyrin-Biroulet L, Filippi J, Pariente B, Roblin X, et al. Effectiveness and safety of vedolizumab induction therapy for patients with inflammatory bowel disease. Clin Gastroenterol Hepatol (2016) 14:1593-601. doi:10.1016/j.cgh.2016.02.016
33. Baumgart DC, Bokemeyer B, Drabik A, Stallmach A, Schreiber S, Vedolizumab Germany Consortium. Vedolizumab induction therapy for inflammatory bowel disease in clinical practice -a nationwide consecutive German cohort study. Aliment Pharmacol Ther (2016) 43:1090-102. doi:10.1111/apt.13594
34. Vermeire S, O'Byrne S, Keir M, Williams M, Lu TT, Mansfield JC, et al. Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial. Lancet (2014) 384:309-18. doi:10.1016/S0140-6736(14)60661-9
35. Zundler S, Schillinger D, Fischer A, Atreya R, López-Posadas R, Watson A, et al. Blockade of αaEβ7 integrin suppresses accumulation of CD8+ and Th9 lymphocytes from patients with IBD in the inflamed gut in vivo. Gut (2016). doi:10.1136/gutjnl-2016-312439
36. Piet B, de Bree GJ, Smids-Dierdorp BS, van der Loos CM, Remmerswaal EBM, von der Thüsen JH, et al. CD8+ T cells with an intraepithelial phenotype upregulate cytotoxic function upon influenza infection in human lung. J Clin Invest (2011) 121:2254-63. doi:10.1172/JCI44675
37. Masson F, Calzascia T, Berardino-Besson WD, de Tribolet N, Dietrich P-Y, Walker PR. Brain microenvironment promotes the final functional maturation of tumor-specific effector CD8+ T cells. J Immunol (2007) 179:845-53. doi:10.4049/jimmunol.179.2.845
38. Annacker O, Coombes JL, Malmstrom V, Uhlig HH, Bourne T, Johansson-Lindbom B, et al. Essential role for CD103 in the T cell-mediated regulation of experimental colitis. J Exp Med (2005) 202:1051-61. doi:10.1084/jem.20040662
39. Coombes JL, Siddiqui KRR, Arancibia-Cárcamo CV, Hall J, Sun C-M, Belkaid Y, et al. A functionally specialized population of mucosal CD103+ DCs induces Foxp3+ regulatory T cells via a TGF-β-and retinoic acid-dependent mechanism. J Exp Med (2007) 204:1757-64. doi:10.1084/jem.20070590
40. Laffont S, Siddiqui KRR, Powrie F. Intestinal inflammation abrogates the tolerogenic properties of MLN CD103+ dendritic cells. Eur J Immunol (2010) 40:1877-83. doi:10.1002/eji.200939957
41. Soler D, Chapman T, Yang L-L, Wyant T, Egan R, Fedyk ER. The binding specificity and selective antagonism of vedolizumab, an anti-α4β7 integrin therapeutic antibody in development for inflammatory bowel diseases. J Pharmacol Exp Ther (2009) 330:864-75. doi:10.1124/jpet.109.153973
42. Vermeire S, Sandborn W, Danese S, Hebuterne X, Salzberg B, Klopocka M, et al. OP021. TURANDOT: a randomized, multicenter double-blind, placebo-controlled study of the safety and efficacy of anti-MAdCAM antibody PF-00547659 (PF) in patients with moderate to severe ulcerative colitis (UC). J Crohns Colitis (2015) 9:S13-13. doi:10.1093/ecco-jcc/jju027.021
43. D'Haens G, Lee S, Tarabar D, Louis E, Klopocka M, Park DI, et al. OP022. Anti-MAdCAM-1 antibody (PF-00547659) for active refractory Crohn's disease: results of the OPERA study. J Crohns Colitis (2015) 9:S14-14. doi:10.1093/ecco-jcc/jju027.022
44. Lamb CA, Mansfield JC, Tew GW, Gibbons D, Long AK, Irving P, et al. αaEβ7 integrin identifies subsets of pro-inflammatory colonic CD4+ T lymphocytes in ulcerative colitis. J Crohns Colitis (2016) 11:610-20. doi:10.1093/ecco-jcc/jjw189
45. Gerlach K, Hwang Y, Nikolaev A, Atreya R, Dornhoff H, Steiner S, et al. TH9 cells that express the transcription factor PU.1 drive T cell-mediated colitis via IL-9 receptor signaling in intestinal epithelial cells. Nat Immunol (2014) 15:676-86. doi:10.1038/ni.2920
46. Gordon FH, Lai CW, Hamilton MI, Allison MC, Srivastava ED, Fouweather MG, et al. A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease. Gastroenterology (2001) 121:268-74. doi:10.1053/gast.2001.26260
47. Ghosh S, Goldin E, Gordon FH, Malchow HA, Rask-Madsen J, Rutgeerts P, et al. Natalizumab for active Crohn's disease. N Engl J Med (2003) 348:24-32. doi:10.1056/NEJMoa020732
48. Targan SR, Feagan BG, Fedorak RN, Lashner BA, Panaccione R, Present DH, et al. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. Gastroenterology (2007) 132:1672-83. doi:10.1053/j.gastro.2007.03.024
49. Loftus EV, Colombel J-F, Feagan BG, Vermeire S, Sandborn WJ, Sands BE, et al. Long-term efficacy of vedolizumab for ulcerative colitis. J Crohns Colitis (2017) 11:400-11. doi:10.1093/ecco-jcc/jjw177
50. Vermeire S, Loftus EV, Colombel J-F, Feagan BG, Sandborn WJ, Sands BE, et al. Long-term efficacy of vedolizumab for Crohn's disease. J Crohns Colitis (2017) 11:412-24. doi:10.1093/ecco-jcc/jjw176
51. Lightner AL, Raffals LE, Mathis KL, Cima RR, Tse CS, Pemberton JH, et al. Postoperative outcomes in vedolizumab-treated patients undergoing abdominal operations for inflammatory bowel disease. J Crohns Colitis (2017) 11:185-90. doi:10.1093/ecco-jcc/jjw147
52. Dulai PS, Singh S, Jiang X, Peerani F, Narula N, Chaudrey K, et al. The real-world effectiveness and safety of vedolizumab for moderate-severe Crohn's disease: results from the US VICTORY consortium. Am J Gastroenterol (2016) 111:1147-55. doi:10.1038/ajg.2016.236
53. Kopylov U, Ron Y, Avni-Biron I, Koslowsky B, Waterman M, Daher S, et al. Efficacy and safety of vedolizumab for induction of remission in inflammatory bowel disease -the Israeli real-world experience. Inflamm Bowel Dis (2017) 23:404-8. doi:10.1097/MIB.0000000000001039
54. Stallmach A, Langbein C, Atreya R, Bruns T, Dignass A, Ende K, et al. Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease -a prospective multicenter observational study. Aliment Pharmacol Ther (2016) 44:1199-212. doi:10.1111/apt.13813
55. Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med (1997) 337:1029-35. doi:10.1056/NEJM199710093371502
56. Tew GW, Hackney JA, Gibbons D, Lamb CA, Luca D, Egen JG, et al. Association between response to etrolizumab and expression of integrin aE and granzyme A in colon biopsies of patients with ulcerative colitis. Gastroenterology (2016) 150:477-87.e9. doi:10.1053/j.gastro.2015.10.041
57. Vermeire S, Ghosh S, Panes J, Dahlerup JF, Luegering A, Sirotiakova J, et al. The mucosal addressin cell adhesion molecule antibody PF-00547,659 in ulcerative colitis: a randomised study. Gut (2011) 60:1068-75. doi:10.1136/gut.2010.226548
58. Vermeire S, Sandborn WJ, Danese S, Hébuterne X, Salzberg BA, Klopocka M, et al. Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet (2017) 390:135-144. doi:10.1016/S0140-6736(17)30930-3
59. Colombel J-F, Sands BE, Rutgeerts P, Sandborn W, Danese S, D'Haens G, et al. The safety of vedolizumab for ulcerative colitis and Crohn's disease. Gut (2017) 66:839-51. doi:10.1136/gutjnl-2015-311079
60. Drvarov O, AbuHashem R, Schunk N, Schreiber S, Kuehbacher T. Tu1346 skin and joint side effects in a subpopulation of anti-TNF experienced IBD patients, who respond to a treatment with vedolizumab, a humanized A4b7 integrin antibody. Gastroenterology (2015) 148:S-865. doi:10.1016/S0016-5085(15)32933-4
61. Lissner D, Sonnenberg E, Glauben R, Allers C, Preiss J, Schneider T, et al. P617 Extraintestinal autoimmune phenomena during treatment with vedolizumab. J Crohns Colitis (2017) 11:S394-5. doi:10.1093/ecco-jcc/jjx002.741
62. Fuchs F, Schillinger D, Atreya R, Hirschmann S, Fischer S, Neufert CF, et al. Clinical response to vedolizumab in UC patients is associated with changes in integrin expression profiles. Front Immunol (2017) 8:764. doi:10.3389/fimmu.2017.00764